PHARMESIS INTERNATIONAL LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 SGD | +50.00% |
|
+50.00% | +22.45% |
| Apr. 15 | Pharmesis’ Attributable Loss for 2023 Widens | MT |
| Apr. 15 | Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 28.9 | 25.53 | 32.33 | 16.13 | 12.91 | 14.45 |
| Enterprise Value (EV) 1 | 9.19 | 26.79 | 33.01 | 19.29 | 9.721 | 21.5 |
| P/E ratio | 22.4 x | -1.44 x | -5.55 x | 13.8 x | -3.63 x | -2.79 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.45 x | 0.69 x | 0.69 x | 0.31 x | 0.26 x | 0.32 x |
| EV / Revenue | 0.14 x | 0.72 x | 0.7 x | 0.37 x | 0.19 x | 0.47 x |
| EV / EBITDA | 2.65 x | -2.96 x | -11 x | 8.27 x | -8.17 x | -3.35 x |
| EV / FCF | -1.65 x | 3.07 x | 10 x | -6.68 x | 1.33 x | -1.7 x |
| FCF Yield | -60.6% | 32.5% | 9.99% | -15% | 75.4% | -58.7% |
| Price to Book | 0.32 x | 0.41 x | 0.57 x | 0.28 x | 0.24 x | 0.28 x |
| Nbr of stocks (in thousands) | 23,000 | 23,000 | 23,000 | 23,000 | 23,000 | 27,600 |
| Reference price 2 | 1.257 | 1.110 | 1.405 | 0.7011 | 0.5611 | 0.5237 |
| Announcement Date | 4/10/19 | 4/8/20 | 4/12/21 | 4/8/22 | 4/12/23 | 4/14/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 64.33 | 37.2 | 47.11 | 52.77 | 50.37 | 45.64 |
| EBITDA 1 | 3.469 | -9.057 | -2.999 | 2.331 | -1.19 | -6.415 |
| EBIT 1 | 1.794 | -10.48 | -4.322 | 1.063 | -2.528 | -7.596 |
| Operating Margin | 2.79% | -28.16% | -9.17% | 2.01% | -5.02% | -16.64% |
| Earnings before Tax (EBT) 1 | 6.112 | -19.53 | -5.838 | 2.116 | -3.158 | -4.858 |
| Net income 1 | 1.289 | -17.67 | -5.827 | 1.17 | -3.56 | -4.958 |
| Net margin | 2% | -47.5% | -12.37% | 2.22% | -7.07% | -10.86% |
| EPS 2 | 0.0560 | -0.7683 | -0.2533 | 0.0509 | -0.1548 | -0.1877 |
| Free Cash Flow 1 | -5.569 | 8.716 | 3.299 | -2.887 | 7.326 | -12.62 |
| FCF margin | -8.66% | 23.43% | 7% | -5.47% | 14.54% | -27.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/10/19 | 4/8/20 | 4/12/21 | 4/8/22 | 4/12/23 | 4/14/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.26 | 0.69 | 3.16 | - | 7.05 |
| Net Cash position 1 | 19.7 | - | - | - | 3.19 | - |
| Leverage (Debt/EBITDA) | - | -0.1391 x | -0.2287 x | 1.356 x | - | -1.099 x |
| Free Cash Flow 1 | -5.57 | 8.72 | 3.3 | -2.89 | 7.33 | -12.6 |
| ROE (net income / shareholders' equity) | 5.25% | -23.6% | -9.57% | 3.32% | -5.42% | -8.82% |
| ROA (Net income/ Total Assets) | 0.89% | -5.89% | -2.92% | 0.72% | -1.66% | -5.17% |
| Assets 1 | 145.4 | 299.8 | 199.7 | 162 | 214.7 | 95.97 |
| Book Value Per Share 2 | 3.920 | 2.700 | 2.450 | 2.500 | 2.340 | 1.850 |
| Cash Flow per Share 2 | 1.510 | 0.6400 | 0.6600 | 0.6100 | 0.8600 | 0.3400 |
| Capex 1 | 4.74 | 6.41 | 0.92 | 1.58 | 0.24 | 0.59 |
| Capex / Sales | 7.36% | 17.24% | 1.95% | 3% | 0.47% | 1.28% |
| Announcement Date | 4/10/19 | 4/8/20 | 4/12/21 | 4/8/22 | 4/12/23 | 4/14/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +22.45% | 2.43M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BFK Stock
- Financials Pharmesis International Ltd.
